HOME >> BIOLOGY >> NEWS
ACS Weekly PressPac -- September 6, 2006

ies of 11 percent, whereas most new solar cells have efficiencies between 4 percent and 5 percent, according to Michael Graetzel, Ph.D., a chemist at the Swiss Federal Institute of Technology, Lausanne.

Graetzel's cells, which can be engineered into inexpensive, flexible sheets, could be used as coatings on glass windows to supply electric power to homes and businesses or as coatings on tents to supply power for soldiers in the field. The cells could be used in consumer applications within two to three years, the researcher says.

CONTACT: Michael Graetzel, Ph.D.
Swiss Federal Institute of Technology
Switzerland
Phone: 41-21-693-3112
Fax: 41-21-693-4111
e-mail: Michael.graetzel@epfl.ch


ARTICLE #3 EMBARGOED FOR: Sunday, Sept. 10, 5:30 p.m., EDT
'Conversation stoppers' fight deadly bacterial infections

NOTE: A press conference on this topic with call-in audio participation will be held at 10 a.m. Sept. 11. Reporters are asked to call five to ten minutes prior to the scheduled start time. Reporters will be asked to identify themselves, their affiliations and the topic of the briefing. Call 800-967-7140 (domestic); 719-457-2629 (international).

Bacterial infections are becoming more deadly worldwide due to increased resistance to antibiotics. Now Helen E. Blackwell and colleagues have developed a powerful strategy to fight these deadly infections: Instead of killing the bacteria directly, the scientists designed a group of compounds that can block the chemical signals that the bacteria use to communicate in an effort to stop their spread.

These compounds, small organic molecules that they call 'conversation stoppers,' could help deliver a powerful one-two punch to knock out deadly infections when combined with the killing power of antibiotics. In addition, these 'conversation stoppers' do not target bac
'"/>

Contact: Michael Woods
m_woods@acs.org
American Chemical Society
12-Sep-2006


Page: 1 2 3 4 5 6 7 8 9

Related biology news :

1. American Chemical Societys Weekly PressPac -- Aug. 8, 2007
2. American Chemical Societys Weekly PressPac -- Aug. 1, 2007
3. American Chemical Societys Weekly PressPac -- July 25, 2007
4. American Chemical Societys Weekly PressPac -- July 18, 2007
5. American Chemical Societys Weekly PressPac -- July 11, 2007
6. American Chemical Societys Weekly PressPac -- June 27/July 3, 2007
7. American Chemical Societys Weekly PressPac -- June 20, 2007
8. American Chemical Societys Weekly PressPac -- June 13, 2007
9. American Chemical Societys Weekly PressPac -- May 30, 2007
10. ACS News Service Weekly PressPac -- May 23, 2007
11. ACS News Service Weekly PressPac -- May 16, 2007

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ACS Weekly PressPac September

(Date:5/7/2015)... , May 7, 2015 ... sensors, FPC1022 and FPC1035, FPC,s smallest touch fingerprint ... are mainly considered for integration on the backside ... smartphone OEMs increased possibilities to integrate touch fingerprint ... size also improves possibilities for module manufacturers to ...
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... NOVATO, Calif. , May 21, 2015 /PRNewswire-USNewswire/ ... Orrin Hatch (R-UT) and Amy ... Product Extensions Now Accelerating Cures & Treatments, or ... 150 rare disease patient advocacy organizations, this bipartisan ... effective, and affordable medicines to rare disease patients ...
(Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ... "2015 Global Survey on Flow Cytometry Adoption Trends" ... primary goal of this research is to analyze ... Key information the survey seeks to collect include ... predominantly used applications for flow cytometers, respondents, most ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: